335 related articles for article (PubMed ID: 25043171)
41. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
42. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Lee HJ; Daver N; Kantarjian HM; Verstovsek S; Ravandi F
Clin Cancer Res; 2013 Jan; 19(2):327-35. PubMed ID: 23209034
[TBL] [Abstract][Full Text] [Related]
43. Beyond JAK inhibitor therapy in myelofibrosis.
Odenike O
Hematology Am Soc Hematol Educ Program; 2013; 2013():545-52. PubMed ID: 24319230
[TBL] [Abstract][Full Text] [Related]
44. Pharmacotherapy of Myelofibrosis.
Tremblay D; Marcellino B; Mascarenhas J
Drugs; 2017 Sep; 77(14):1549-1563. PubMed ID: 28791654
[TBL] [Abstract][Full Text] [Related]
45. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
Tefferi A; Pardanani A
Blood Rev; 2011 Sep; 25(5):229-37. PubMed ID: 21742423
[TBL] [Abstract][Full Text] [Related]
46. Rationale for combination therapy in myelofibrosis.
Mascarenhas J
Best Pract Res Clin Haematol; 2014 Jun; 27(2):197-208. PubMed ID: 25189730
[TBL] [Abstract][Full Text] [Related]
47. Emerging drugs for the treatment of Myelofibrosis.
Shreenivas A; Mascarenhas J
Expert Opin Emerg Drugs; 2018 Mar; 23(1):37-49. PubMed ID: 29480036
[TBL] [Abstract][Full Text] [Related]
48. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.
Mascarenhas J; Hoffman R
Clin Cancer Res; 2012 Jun; 18(11):3008-14. PubMed ID: 22474318
[TBL] [Abstract][Full Text] [Related]
49. A potential role of ruxolitinib in leukemia.
Naqvi K; Verstovsek S; Kantarjian H; Ravandi F
Expert Opin Investig Drugs; 2011 Aug; 20(8):1159-66. PubMed ID: 21635221
[TBL] [Abstract][Full Text] [Related]
50. Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms.
Kaplan JB; Stein BL; McMahon B; Giles FJ; Platanias LC
EBioMedicine; 2016 Jan; 3():17-25. PubMed ID: 26870834
[TBL] [Abstract][Full Text] [Related]
51. Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib.
Fournier JB; Cummings F; Cannella J; Breen C; Zhou L; Iwamoto S
Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526003
[TBL] [Abstract][Full Text] [Related]
52. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
[TBL] [Abstract][Full Text] [Related]
53. The new landscape of therapy for myelofibrosis.
Gowin K; Emanuel R; Geyer H; Mesa RA
Curr Hematol Malig Rep; 2013 Dec; 8(4):325-32. PubMed ID: 24101258
[TBL] [Abstract][Full Text] [Related]
54. Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy.
Harrington PM; Harrison CN
Expert Rev Hematol; 2018 Apr; 11(4):315-324. PubMed ID: 29516749
[TBL] [Abstract][Full Text] [Related]
55. Novel Therapies for Myelofibrosis.
Pettit K; Odenike O
Curr Hematol Malig Rep; 2017 Dec; 12(6):611-624. PubMed ID: 29098608
[TBL] [Abstract][Full Text] [Related]
56. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
Expert Opin Ther Pat; 2017 Feb; 27(2):145-161. PubMed ID: 27774822
[TBL] [Abstract][Full Text] [Related]
57. Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway.
Vafadari R; Weimar W; Baan CC
Clin Chim Acta; 2012 Sep; 413(17-18):1398-405. PubMed ID: 22261016
[TBL] [Abstract][Full Text] [Related]
58. Paradigm shift: combination BET and JAK inhibition in myelofibrosis.
Mascarenhas J; Gerds A; Verstovsek S
Leukemia; 2021 Dec; 35(12):3361-3363. PubMed ID: 34480105
[No Abstract] [Full Text] [Related]
59. Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?
Breccia M; Molica M; Colafigli G; Alimena G
Expert Rev Hematol; 2015 Aug; 8(4):387-9. PubMed ID: 25915176
[TBL] [Abstract][Full Text] [Related]
60. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
Tefferi A
Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
